Anthropic Quietly Builds Its Own Biology Lab as It Pushes Deeper Into AI Drug Discovery
Quick Reads
- Anthropic, the maker of Claude AI, has quietly built real physical labs to research and discover new drugs.
- It acquired a startup, Coefficient Bio, for about $400 million to boost its drug-development expertise.
- The focus is on diseases big pharma often ignores but no AI-designed drug has passed clinical trials yet.
Anthropic AI Drug Discovery.
Anthropic, the company known for its Claude AI models, is now getting into medicine. It has quietly built real laboratories not just software and is using artificial intelligence to try to discover new drugs.
Who Is Leading This?
The project is led by Eric Kauderer-Abrams. He joined Anthropic about ten months ago from a diagnostics startup to build this team almost from scratch. His goal is bold: use AI to make drug research up to ten times faster than it is today.
What Anthropic Is Actually Doing
Anthropic is training its Claude AI on biology topics from how proteins are structured to how drug approvals work. It has also opened its own labs to run early-stage research and bought a startup called Coefficient Bio for about $400 million. That deal brought in experts who know how to pick promising drug targets and plan real biotech programs.
Instead of only selling AI tools to drug companies, Anthropic wants to develop its own medicines especially for diseases that big pharmaceutical companies often skip because they’re not profitable enough.
Why It’s Not That Simple
Anthropic itself admits biology is much harder to teach AI than subjects like math or coding, because there isn’t always one clear “right answer” in biology. And experts warn that no AI-designed drug has ever made it all the way through clinical trials to approval yet.
